Five new Novartis drugs were approved in Japan yesterday.

On June 29th Novartis announced that five of its new drugs had been approved for listing by Japan's Ministry of Health, Labour and Welfare.
so far, Novartis has approved seven products in Japan by 2020.

a brief introduction to the five products approved today: Tabrecta Tabrecta (Camatinib), a c-MET inhibitor, was approved by the FDA on May 6 to treat patients with non-small cell lung cancer (NSCLC) with locally advanced or metastatic metexosome 14 jump (METEX 14) mutations.
Entresto Entresto, a heart failure treatment, was approved by the FDA in July 2015 and approved for entry into China in July 2017, with a product called Nosinto, and negotiated entry into the National Health Insurance Category B catalog in 2019.
Novinto's sales reached $1.726 billion in 2019.
Mayzent Mayzent (Sinimod) is a new generation of selective amol 1-phosphate receptor regulator, approved by the FDA in March 2019, in May 2020 approved to enter China, the commodity rice is Universal Energy.
Mayzent is the FDA's first and only drug in 15 years dedicated to the treatment of active secondary progressive multiple sclerosis.
Enerzair Enerzair (Grun Bromine-Datero-Momissin) is a daily corticosteroid/long-acting M-receptor blocker/long-acting beta-receptor agonist (ICS/LAMA/LABA) triple compound formulation and the world's first approved ICS/LAMA/LABA triple compound for asthma, which is currently on the market in China.
Atectura Atectura (Datero-Momissin) is a LABA/ICS dicombination formulation, mainly used for asthma.
, the drug has also been submitted for listing in China.
.